Compare Spotify Technology (SPOT) vs 10X Genomics Inc (TXG) Price & Performance

Spotify (SPOT) trades at $512.92, up 5.08% with strong bullish momentum. The stock shows robust fundamentals with revenue growth from $17.19B in 2025 to projected $18.1B in 2026, while net income margin expanded to 18.43%. Technical indicators signal bullish sentiment with price above key support at $497. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results pending.

Outlook remains positive with analyst consensus target of $608.18 representing 18.6% upside. Key opportunities include gross margin expansion and new monetization tools, while risks involve competitive pressures and market volatility. Wall Street maintains strong buy sentiment with 62% of analysts recommending purchase.

10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.

The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.